Association of Cardiometabolic Multimorbidity With Mortality

Abstract

The Emerging Risk Factors Collaboration IMPORTANCE The prevalence of cardiometabolic multimorbidity is increasing. OBJECTIVE To estimate reductions in life expectancy associated with cardiometabolic multimorbidity. DESIGN, SETTING, AND PARTICIPANTS Age-and sex-adjusted mortality rates and hazard ratios (HRs) were calculated using individual participant data from the Emerging Risk Factors Collaboration (689 300 participants; 91 cohorts; years of baseline surveys: 1960-2007; latest mortality follow-up: April 2013; 128 843 deaths). The HRs from the Emerging Risk Factors Collaboration were compared with those from the UK Biobank (499 808 participants; years of baseline surveys: 2006-2010; latest mortality follow-up: November 2013; 7995 deaths).Cumulative survival was estimated by applying calculated age-specific HRs for mortality to contemporary US age-specific death rates.EXPOSURES A history of 2 or more of the following: diabetes mellitus, stroke, myocardial infarction (MI). MAIN OUTCOMES AND MEASURESAll-cause mortality and estimated reductions in life expectancy. RESULTSIn participants in the Emerging Risk Factors Collaboration without a history of diabetes, stroke, or MI at baseline (reference group), the all-cause mortality rate adjusted to the age of 60 years was 6.8 per 1000 person-years. Mortality rates per 1000 person-years were 15.6 in participants with a history of diabetes, 16.1 in those with stroke, 16.8 in those with MI, 32.0 in those with both diabetes and MI, 32.5 in those with both diabetes and stroke, 32.8 in those with both stroke and MI, and 59.5 in those with diabetes, stroke, and MI. Compared with the reference group, the HRs for all-cause mortality were 1.9 (95% CI, 1.8-2.0) in participants with a history of diabetes, 2.1 (95% CI, 2.0-2.2) in those with stroke, 2.0 (95% CI, 1.9-2.2) in those with MI, 3.7 (95% CI, 3.3-4.1) in those with both diabetes and MI, 3.8 (95% CI, 3.5-4.2) in those with both diabetes and stroke, 3.5 (95% CI, 3.1-4.0) in those with both stroke and MI, and 6.9 (95% CI, 5.7-8.3) in those with diabetes, stroke, and MI. The HRs from the Emerging Risk Factors Collaboration were similar to those from the more recently recruited UK Biobank. The HRs were little changed after further adjustment for markers of established intermediate pathways (eg, levels of lipids and blood pressure) and lifestyle factors (eg, smoking, diet). At the age of 60 years, a history of any 2 of these conditions was associated with 12 years of reduced life expectancy and a history of all 3 of these conditions was associated with 15 years of reduced life expectancy. CONCLUSIONS AND RELEVANCEMortality associated with a history of diabetes, stroke, or MI was similar for each condition. Because any combination of these conditions was associated with multiplicative mortality risk, life expectancy was substantially lower in people with multimorbidity.

Cardiovascular Safety, Long‐Term Noncardiovascular Safety, and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta‐Analysis With Trial Sequential Analysis

“…Type 2 diabetes mellitus (DM) is a systemic disease associated with an increased risk of cardiovascular complications 1. Previous studies emphasized the glucose‐lowering effects of antihyperglycemic drugs but often did not evaluate their ability to reduce the long‐term complications of DM 2.…”

2016 European Guidelines on cardiovascular disease prevention in clinical practice

“…402 People with DM with existing CAD have a vascular risk well in excess of those with CAD but without DM and a substantially lower life expectancy. 409 Statins are recommended for all those newly diagnosed with type 2 DM beyond a certain age (.40 years is currently recommended). This recommendation reflects greater lifetime vascular risk trajectories in these individuals.…”

Development and piloting of a highly tailored text and voice messaging intervention to support adherence to antihypertensive medications within the primary care setting (Preprint)

“…Hypertension or high blood pressure, affects approximately one in four people in England [1], and often accompanies other conditions, including type 2 diabetes mellitus, coronary heart disease and stroke [2]. These conditions are major risk factors for disability and premature death [2], and medication adherence can significantly lower these risks [1].…”

“…These conditions are major risk factors for disability and premature death [2], and medication adherence can significantly lower these risks [1]. For example, in England over ten years, an estimated 7,000 quality of life years could be saved and £120m not spent on related health and social care, if people had better adherence to anti-hypertensive medications [3].…”